| |
[摘要]：JX-594 is derived by inserting human GMCSF genes under the control of earlyllote promoters into the thymidine kinase (TK) genes of the vaccinia virus. JX-594 was well tolerated when administered intratumorally to patients with surgically incurable melanoma twice weekly at doses up to 2 x 10(7) PFU/lesion and up to 8 x 10(7) PFU/session. Three of the seven patients had complete or partial responses in their treated and untreated lesions. In on additional dose-escalation study, intratumoral injection of JX-594 (10(8) PFU, 3 x 10(8) PFU, 10(9) PFU or 3 x 10(9) PFU) every 3 weeks (1-8 doses) into primary or metastatic liver tumors was generally well tolerated. Direct hyperbilirubinemia was the dose-limiting toxicity at 3 x 10(9) PFU. Overall safety was acceptable in the context of JX-594 replication, GM-CSF expression and systemic dissemination, and JX-594 had antitumor effects against several refractory carcinomas. |
|
